We are live on ! Find out more
PSC

Patient Square Capital Portfolio holdings

AUM $646M
1-Year Est. Return 291.07%
This Fund
S&P 500
This Quarter Est. Return
+24.89%
1 Year Est. Return
+291.07%
3 Year Est. Return
+328.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$81.9M
Cap. Flow
-$14.5M
Cap. Flow %
-2.25%
Top 10 Hldgs %
80.13%
Holding
35
New
6
Increased
9
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$40.3M
2
UTHR icon
United Therapeutics
UTHR
+$20.9M
3
BNTX icon
BioNTech
BNTX
+$12.7M
4
ABVX
Abivax
ABVX
+$9.65M
5
IVA
Inventiva
IVA
+$9.45M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$25.8M
2
LEGN icon
Legend Biotech
LEGN
+$17.9M
3
NKTR icon
Nektar Therapeutics
NKTR
+$15.1M
4
ARGX icon
argenx
ARGX
+$11.3M
5
CELC icon
Celcuity
CELC
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELC icon
26
Celcuity
CELC
$4.15B
– –
-95,000
Closed -$10.8M
CTMX icon
27
CytomX Therapeutics
CTMX
$614M
– –
-1,085,790
Closed -$5.1M
HROW icon
28
Harrow
HROW
$1.24B
– –
-165,209
Closed -$5.83M
INSM icon
29
Insmed
INSM
$27.1B
– –
-157,500
Closed -$25.8M
LEGN icon
30
Legend Biotech
LEGN
$3.42B
– –
-990,000
Closed -$17.9M
DFTX
31
Definium Therapeutics
DFTX
$5.2B
– –
-331,000
Closed -$6.26M
MRK icon
32
Merck
MRK
$363B
– –
-80,000
Closed -$9.62M
NKTR icon
33
Nektar Therapeutics
NKTR
$2.33B
– –
-210,000
Closed -$15.1M
SYRE icon
34
Spyre Therapeutics
SYRE
$8.17B
– –
-1,000
Closed -$50.4K
TARA icon
35
Protara Therapeutics
TARA
$219M
– –
-1,030,846
Closed -$5.37M
1
2

Similar funds

WW
Waterfront Wealth Overland Park, Kansas $645M AUM 27.59% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $646M AUM 32.22% 1-Year Est. Return
LFS
Legacy Financial Strategies Overland Park, Kansas $646M AUM 23.5% 1-Year Est. Return
CAMV
Concord Asset Management (Virginia) Abingdon, Virginia $646M AUM 25.36% 1-Year Est. Return
BCB
Brian C. Broderick $646M AUM 43.3% 1-Year Est. Return
ML
Mayport LLC Newton, Massachusetts $645M AUM 19.45% 1-Year Est. Return
JCP
JB Capital Partners Armonk, New York $646M AUM 39.9% 1-Year Est. Return
HIS
Harvest Investment Services Oakbrook Terrace, Illinois $647M AUM 89.3% 1-Year Est. Return

Patient Square Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Patient Square Capital held 35 positions worth $646M, up 15% from $564M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Patient Square Capital's Q2 2026 filing shows 6 new, 9 increased, 8 reduced and 12 closed positions. Its largest new stake was Revolution Medicines: 276,000 shares worth $51.7M. The largest sale was Insmed, an estimated $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Patient Square Capital's largest Q2 2026 buy was Revolution Medicines: 276,000 shares worth $51.7M.
  • Patient Square Capital added most to Abivax in Q2 2026, an estimated $9.65M increase.
  • Patient Square Capital's biggest Q2 2026 reduction was argenx, cutting an estimated $11.3M.
  • Patient Square Capital fully exited Insmed in Q2 2026, selling an estimated $25.8M.
  • Patient Square Capital's ten largest holdings make up 80% of its $646M portfolio in Q2 2026.
  • Patient Square Capital opened 6 new positions and closed 12 in Q2 2026.
  • Patient Square Capital's portfolio value rose 15% quarter-over-quarter to $646M.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.